Table 2.
Apolipoprotein E4 Allele Prevalence by Outcome in the UK Biobank
| Variable Type | Phenotype (n [% of total] | E4 Carrier (n = 126 082) | No E4 Allele (n = 312 629) | Odds Ratio [95% CI] | P |
|---|---|---|---|---|---|
| Primary outcome | Glaucoma | 3867 [3.1%] | 10 121 [3.2%] | 0.96 [0.93,0.99] | 0.016 |
| Positive control | Alzheimer’s dementia | 1198 [1.0%] | 1172 [0.2%] | 3.56 [3.33,3.81] | < 0.001 |
| Death | 9625 [7.6%] | 21 603 [6.9%] | 1.07 [1.05,1.10] | < 0.001 | |
| AMD | 2771 [2.2%] | 7704 [2.5%] | 0.91 [0.87,0.94] | < 0.001 | |
| Negative control | Cataract | 15 983 [12.7%] | 40 911 [13.1%] | 0.98 [0.96,0.99] | 0.015 |
| Diabetic eye disease | 1316 [1.0%] | 3518 [1.1%] | 0.92 [0.87,0.97] | 0.003 |
Correlation between the Apolipoprotein E4 allele and glaucoma in the UK Biobank. Alzheimer’s dementia (AD), death, and age-related macular degeneration (AMD) are included as positive controls because of established associations with the E4 allele. Cataract and diabetic eye disease are included as negative controls. Odds ratios and P values have been generated using logistic regression to determine a per allele effect on the outcome variable. Adjustments for the E2 allele, age (squared), sex, and "AD diagnosis" were included in analysis. CI = confidence interval.